• Compare Products
Menu
Account
Make more informed purchasing decisions with our new product availability and delivery estimate feature, now available on all product pages, in your cart, and during checkout.

ImmunoCult™ Human CD3/CD28 T Cell Activator

cGMP, human T cell activation and expansion reagent

Loading...
 
 

ImmunoCult™ Human CD3/CD28 T Cell Activator

cGMP, human T cell activation and expansion reagent

From: 3,599 USD
Catalog #
(Select a product)
cGMP, human T cell activation and expansion reagent
Add to Wish List

Product Advantages

  • Activate T cells with confidence for use in clinical applications using activators produced under relevant cGMPs
  • Achieve robust activation without the use of magnetic beads, feeder cells, or antigens
  • Maintain a high viability of activated and expanded T cells with gentle activation stimulus
  • Rely on a highly stable, filter-sterilized soluble reagent

Overview

Achieve robust activation and expansion of human T cells for use in clinical applications–without the use of magnetic beads, feeder cells, or antigens.

This product’s gentle activation stimulus ensures a high viability of activated T cells, which can be further expanded in ImmunoCult™-XF—a high-performance T cell expansion medium manufactured under relevant cGMP regulations and guidelines. ImmunoCult™ Human CD3/CD28 T Cell Activator consists of soluble antibody complexes that bind to and cross-link CD3 and CD28 cell surface ligands, thereby providing the required primary and co-stimulatory signals for T cell culture and activation.

ImmunoCult™ Human CD3/CD28 T Cell Activator is designed for cell therapy clinical research applications by qualifying it for use as an ancillary material (AM) following the framework outlined in USP<1043> and/or PH. EUR. 5.2.12. STEMCELL can work with you to qualify this reagent as an AM under an approved Investigational New Drug (IND) application, Biological Licensing Application (BLA), or Clinical Trial Application (CTA). Learn more about how we can support your regulatory needs here.
Contains
• Anti-human CD3 monospecific antibody complex
• Anti-human CD28 monospecific antibody complex
• Phosphate buffered-saline (PBS), containing 0.02% TWEEN® 20
Subtype
Supplements
Cell Type
T Cells, T Cells, CD4+, T Cells, CD8+
Species
Human
Application
Activation, Cell Culture, Expansion
Brand
ImmunoCult
Area of Interest
Cancer, Immunology, Cell Therapy Development

Data Figures

Activated human T cells clustering together.

Figure 1. Morphology of Activated Human T Cells Stimulated with ImmunoCult™ Human CD3/CD28 T Cell Activator

A clustered morphology is seen in activated human T cells. Cells were isolated using EasySep™ Human T Cell Isolation Kit, stimulated with ImmunoCult™ Human CD3/CD28 T Cell Activator for 3 days in ImmunoCult™-XF supplemented with recombinant human interleukin-2 (rhIL-2).

Flow cytometry data showing human T cell activation assessed by CD25 expression.

Figure 2. Activation of Human T Cells Stimulated with ImmunoCult™ Human CD3/CD28 Activator.

Human T cells were stimulated with ImmunoCult™ Human CD3/CD28 T Cell Activator and cultured in ImmunoCult™-XF . Activation of viable CD4+ and CD8+ T cells were assessed by CD25 expression, using flow cytometry. Following 3 days of culture, the frequency of CD25-positive cells was (A) 75.5% for CD4+ T cells and (B) 65.3% for CD8+ T cells . The gray line depicts day 3 CD4+ and CD8+ T cells cultured without ImmunoCult™ Human CD3/CD28 T Cell Activator.

Human T cell cumulative fold expansion and activation during a 12-day culture period.

Figure 3. Robust Human T Cell Expansion and High Viability Achieved Using ImmunoCult™ Human CD3/CD28 T Cell Activator

Human T cells were expanded over 12 days with ImmunoCult™ Human CD3/CD28 T Cell Activator in ImmunoCult™-XF supplemented with rhIL-2. On day 0, 1 x 10^6 isolated human T cells were stimulated with 25 μL of ImmunoCult™ Human CD3/CD28 T Cell Activator in ImmunoCult™-XF supplemented rhIL-2. No additional ImmunoCult™ Human CD3/CD28 T Cell Activator was added during the 12-day culture period (mean ± SD in 3 experiments with 7 donors).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
ImmunoCult™ Human CD3/28 T Cell Activator
Catalog #
100-0784
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
ImmunoCult™ Human CD3/28 T Cell Activator
Catalog #
100-0784
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Research Area
Workflow Stages

Resources and Publications

Educational Materials (9)

Use cGMP-Manufactured ImmunoCult™-XF
Brochure
Use cGMP-Manufactured ImmunoCult™-XF
T Cell Reagents for Your Cellular Therapy Research
Brochure
T Cell Reagents for Your Cellular Therapy Research
Production of Chimeric Antigen Receptor T Cells
Wallchart
Production of Chimeric Antigen Receptor T Cells
Roundtable: Improving Collaboration Between Industry and Academia in the Field of CAR T Cell Therapy
44:53
Webinar
Roundtable: Improving Collaboration Between Industry and Academia in the Field of CAR T Cell Therapy
How to Optimize Your T Cell Therapy Workflow—Without the Use of Serum or Feeder Cells
27:26
Webinar
How to Optimize Your T Cell Therapy Workflow—Without the Use of Serum or Feeder Cells
Non-Viral CRISPR Knock-In Anti-B7-H3 CAR-T Cells Are Amenable for Treatment of Subtypes of Small Cell Lung Cancer
26:48
Webinar
Non-Viral CRISPR Knock-In Anti-B7-H3 CAR-T Cells Are Amenable for Treatment of Subtypes of Small Cel...
Combining CAR T Cells with STING Agonists to Fight Solid Tumors
52:59
Webinar
Combining CAR T Cells with STING Agonists to Fight Solid Tumors
Key Regulatory Considerations for Moving Your Cell Therapy Research to the Clinic
28:34
Webinar
Key Regulatory Considerations for Moving Your Cell Therapy Research to the Clinic
Next-Generation Cell Isolation Solutions for T Cell Therapy Research
27:28
Webinar
Next-Generation Cell Isolation Solutions for T Cell Therapy Research

Related Products

Related Products

Quality Statement:

THIS PRODUCT IS MANUFACTURED AND TESTED FOLLOWING RELEVANT CGMPs UNDER A CERTIFIED QUALITY MANAGEMENT SYSTEM. PRODUCT IS FOR INVESTIGATIONAL OR RESEARCH USE. NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.

Copyright © 2024 by STEMCELL Technologies. All rights reserved.